Do analysts prefer VVOS or VBIO?

Vivos Therapeutics presently has a consensus target price of $2.80, indicating a potential upside of 612.29%. Given Vivos Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Vivos Therapeutics is more favorable than Valion Bio, Inc. Common Stock. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vivos Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Valion Bio, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend PAVM or VBIO?

PAVmed presently has a consensus target price of $56.00, indicating a potential upside of 1,081.43%. Given PAVmed's stronger consensus rating and higher possible upside, analysts clearly believe PAVmed is more favorable than Valion Bio, Inc. Common Stock. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PAVmed 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Valion Bio, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer PAVM or VBIO?

In the previous week, Valion Bio, Inc. Common Stock had 3 more articles in the media than PAVmed. MarketBeat recorded 5 mentions for Valion Bio, Inc. Common Stock and 2 mentions for PAVmed. PAVmed's average media sentiment score of 0.93 beat Valion Bio, Inc. Common Stock's score of 0.17 indicating that PAVmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PAVmed 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Valion Bio, Inc. Common Stock 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate VBIO or ITOC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Valion Bio, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Itonic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, VBIO or ITOC?

Itonic has higher revenue and earnings than Valion Bio, Inc. Common Stock. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Valion Bio, Inc. Common Stock N/A N/A -$8.88M -$6.68 N/A Itonic $520K 8.69 -$5.10M N/A N/A

Is VBIO or ITOC more profitable?

Itonic's return on equity of 0.00% beat Valion Bio, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Valion Bio, Inc. Common Stock N/A -138.10% -63.67% Itonic N/A N/A N/A

Do analysts rate VBIO or INBS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Valion Bio, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Intelligent Bio Solutions 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Do analysts prefer VBIO or CLGN?

CollPlant Biotechnologies has a consensus price target of $11.50, suggesting a potential upside of 3,550.79%. Given CollPlant Biotechnologies' stronger consensus rating and higher possible upside, analysts clearly believe CollPlant Biotechnologies is more favorable than Valion Bio, Inc. Common Stock. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Valion Bio, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CollPlant Biotechnologies 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Valion Bio, Inc. Common Stock (VBIO) Competitors

$0.30 +0.01 (+3.85%)

As of 07/24/2026 04:00 PM Eastern

Compare

VBIO vs. VVOS, PAVM, ITOC, INBS, and CLGN

Should you buy Valion Bio, Inc. Common Stock stock or one of its competitors? MarketBeat compares Valion Bio, Inc. Common Stock with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Valion Bio, Inc. Common Stock include Vivos Therapeutics (VVOS), PAVmed (PAVM), Itonic (ITOC), Intelligent Bio Solutions (INBS), and CollPlant Biotechnologies (CLGN). These companies are all part of the "medical equipment" industry.

How does Valion Bio, Inc. Common Stock compare to Vivos Therapeutics?

Vivos Therapeutics (NASDAQ:VVOS) and Valion Bio, Inc. Common Stock (NASDAQ:VBIO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability and risk.

Valion Bio, Inc. Common Stock has a net margin of 0.00% compared to Vivos Therapeutics' net margin of -127.70%. Valion Bio, Inc. Common Stock's return on equity of -138.10% beat Vivos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vivos Therapeutics	-127.70%	-2,325.64%	-98.12%
Valion Bio, Inc. Common Stock	N/A	-138.10%	-63.67%

Vivos Therapeutics has a beta of 6.16, indicating that its stock price is 516% more volatile than the broader market. Comparatively, Valion Bio, Inc. Common Stock has a beta of 1.82, indicating that its stock price is 82% more volatile than the broader market.

Vivos Therapeutics presently has a consensus target price of $2.80, indicating a potential upside of 612.29%. Given Vivos Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Vivos Therapeutics is more favorable than Valion Bio, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivos Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Valion Bio, Inc. Common Stock had 4 more articles in the media than Vivos Therapeutics. MarketBeat recorded 5 mentions for Valion Bio, Inc. Common Stock and 1 mentions for Vivos Therapeutics. Vivos Therapeutics' average media sentiment score of 1.52 beat Valion Bio, Inc. Common Stock's score of 0.17 indicating that Vivos Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Vivos Therapeutics	Very Positive
Valion Bio, Inc. Common Stock	Neutral

26.4% of Vivos Therapeutics shares are held by institutional investors. Comparatively, 4.3% of Valion Bio, Inc. Common Stock shares are held by institutional investors. 2.1% of Vivos Therapeutics shares are held by company insiders. Comparatively, 2.2% of Valion Bio, Inc. Common Stock shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valion Bio, Inc. Common Stock has lower revenue, but higher earnings than Vivos Therapeutics. Vivos Therapeutics is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivos Therapeutics	$19.57M	0.28	-$21.17M	-$2.14	N/A
Valion Bio, Inc. Common Stock	N/A	N/A	-$8.88M	-$6.68	N/A

Summary

Vivos Therapeutics beats Valion Bio, Inc. Common Stock on 8 of the 15 factors compared between the two stocks.

How does Valion Bio, Inc. Common Stock compare to PAVmed?

PAVmed (NASDAQ:PAVM) and Valion Bio, Inc. Common Stock (NASDAQ:VBIO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

19.9% of PAVmed shares are owned by institutional investors. Comparatively, 4.3% of Valion Bio, Inc. Common Stock shares are owned by institutional investors. 13.4% of PAVmed shares are owned by company insiders. Comparatively, 2.2% of Valion Bio, Inc. Common Stock shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

PAVmed presently has a consensus target price of $56.00, indicating a potential upside of 1,081.43%. Given PAVmed's stronger consensus rating and higher possible upside, analysts clearly believe PAVmed is more favorable than Valion Bio, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PAVmed	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

PAVmed has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market. Comparatively, Valion Bio, Inc. Common Stock has a beta of 1.82, suggesting that its stock price is 82% more volatile than the broader market.

Valion Bio, Inc. Common Stock has a net margin of 0.00% compared to PAVmed's net margin of -21,914.12%. Valion Bio, Inc. Common Stock's return on equity of -138.10% beat PAVmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PAVmed	-21,914.12%	-146.19%	-18.39%
Valion Bio, Inc. Common Stock	N/A	-138.10%	-63.67%

PAVmed has higher revenue and earnings than Valion Bio, Inc. Common Stock. PAVmed is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PAVmed	$70K	67.71	$400K	-$37.40	N/A
Valion Bio, Inc. Common Stock	N/A	N/A	-$8.88M	-$6.68	N/A

In the previous week, Valion Bio, Inc. Common Stock had 3 more articles in the media than PAVmed. MarketBeat recorded 5 mentions for Valion Bio, Inc. Common Stock and 2 mentions for PAVmed. PAVmed's average media sentiment score of 0.93 beat Valion Bio, Inc. Common Stock's score of 0.17 indicating that PAVmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PAVmed	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Valion Bio, Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

PAVmed beats Valion Bio, Inc. Common Stock on 9 of the 15 factors compared between the two stocks.

How does Valion Bio, Inc. Common Stock compare to Itonic?

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) and Itonic (NASDAQ:ITOC) are both small-cap medical equipment companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.

Valion Bio, Inc. Common Stock has a beta of 1.82, suggesting that its stock price is 82% more volatile than the broader market. Comparatively, Itonic has a beta of 2.75, suggesting that its stock price is 175% more volatile than the broader market.

Itonic has higher revenue and earnings than Valion Bio, Inc. Common Stock.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valion Bio, Inc. Common Stock	N/A	N/A	-$8.88M	-$6.68	N/A
Itonic	$520K	8.69	-$5.10M	N/A	N/A

In the previous week, Valion Bio, Inc. Common Stock had 4 more articles in the media than Itonic. MarketBeat recorded 5 mentions for Valion Bio, Inc. Common Stock and 1 mentions for Itonic. Itonic's average media sentiment score of 1.89 beat Valion Bio, Inc. Common Stock's score of 0.17 indicating that Itonic is being referred to more favorably in the news media.

Company	Overall Sentiment
Valion Bio, Inc. Common Stock	Neutral
Itonic	Very Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Itonic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

4.3% of Valion Bio, Inc. Common Stock shares are held by institutional investors. 2.2% of Valion Bio, Inc. Common Stock shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Itonic's return on equity of 0.00% beat Valion Bio, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valion Bio, Inc. Common Stock	N/A	-138.10%	-63.67%
Itonic	N/A	N/A	N/A

Summary

Itonic beats Valion Bio, Inc. Common Stock on 6 of the 9 factors compared between the two stocks.

How does Valion Bio, Inc. Common Stock compare to Intelligent Bio Solutions?

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) and Intelligent Bio Solutions (NASDAQ:INBS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk, media sentiment and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Intelligent Bio Solutions	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Valion Bio, Inc. Common Stock has a net margin of 0.00% compared to Intelligent Bio Solutions' net margin of -296.73%. Valion Bio, Inc. Common Stock's return on equity of -138.10% beat Intelligent Bio Solutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valion Bio, Inc. Common Stock	N/A	-138.10%	-63.67%
Intelligent Bio Solutions	-296.73%	-176.09%	-89.71%

In the previous week, Valion Bio, Inc. Common Stock had 1 more articles in the media than Intelligent Bio Solutions. MarketBeat recorded 5 mentions for Valion Bio, Inc. Common Stock and 4 mentions for Intelligent Bio Solutions. Intelligent Bio Solutions' average media sentiment score of 0.68 beat Valion Bio, Inc. Common Stock's score of 0.17 indicating that Intelligent Bio Solutions is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Valion Bio, Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Intelligent Bio Solutions	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Valion Bio, Inc. Common Stock has a beta of 1.82, suggesting that its stock price is 82% more volatile than the broader market. Comparatively, Intelligent Bio Solutions has a beta of 4.18, suggesting that its stock price is 318% more volatile than the broader market.

Valion Bio, Inc. Common Stock has higher earnings, but lower revenue than Intelligent Bio Solutions. Intelligent Bio Solutions is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valion Bio, Inc. Common Stock	N/A	N/A	-$8.88M	-$6.68	N/A
Intelligent Bio Solutions	$3.91M	1.07	-$10.57M	-$12.22	N/A

4.3% of Valion Bio, Inc. Common Stock shares are owned by institutional investors. Comparatively, 33.0% of Intelligent Bio Solutions shares are owned by institutional investors. 2.2% of Valion Bio, Inc. Common Stock shares are owned by company insiders. Comparatively, 1.3% of Intelligent Bio Solutions shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Valion Bio, Inc. Common Stock beats Intelligent Bio Solutions on 8 of the 13 factors compared between the two stocks.

How does Valion Bio, Inc. Common Stock compare to CollPlant Biotechnologies?

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) and CollPlant Biotechnologies (NASDAQ:CLGN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, media sentiment, profitability and dividends.

Valion Bio, Inc. Common Stock has a beta of 1.82, meaning that its share price is 82% more volatile than the broader market. Comparatively, CollPlant Biotechnologies has a beta of 1.6, meaning that its share price is 60% more volatile than the broader market.

Valion Bio, Inc. Common Stock has higher earnings, but lower revenue than CollPlant Biotechnologies. CollPlant Biotechnologies is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valion Bio, Inc. Common Stock	N/A	N/A	-$8.88M	-$6.68	N/A
CollPlant Biotechnologies	$2.37M	1.92	-$11.49M	-$1.45	N/A

CollPlant Biotechnologies has a consensus price target of $11.50, suggesting a potential upside of 3,550.79%. Given CollPlant Biotechnologies' stronger consensus rating and higher possible upside, analysts clearly believe CollPlant Biotechnologies is more favorable than Valion Bio, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CollPlant Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

4.3% of Valion Bio, Inc. Common Stock shares are held by institutional investors. Comparatively, 21.7% of CollPlant Biotechnologies shares are held by institutional investors. 2.2% of Valion Bio, Inc. Common Stock shares are held by company insiders. Comparatively, 9.6% of CollPlant Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valion Bio, Inc. Common Stock has a net margin of 0.00% compared to CollPlant Biotechnologies' net margin of -683.68%. Valion Bio, Inc. Common Stock's return on equity of -138.10% beat CollPlant Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valion Bio, Inc. Common Stock	N/A	-138.10%	-63.67%
CollPlant Biotechnologies	-683.68%	-218.81%	-139.28%

In the previous week, Valion Bio, Inc. Common Stock had 3 more articles in the media than CollPlant Biotechnologies. MarketBeat recorded 5 mentions for Valion Bio, Inc. Common Stock and 2 mentions for CollPlant Biotechnologies. CollPlant Biotechnologies' average media sentiment score of 1.43 beat Valion Bio, Inc. Common Stock's score of 0.17 indicating that CollPlant Biotechnologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Valion Bio, Inc. Common Stock	Neutral
CollPlant Biotechnologies	Positive

Summary

CollPlant Biotechnologies beats Valion Bio, Inc. Common Stock on 8 of the 15 factors compared between the two stocks.

Get Valion Bio, Inc. Common Stock News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VBIO vs. The Competition

Export

Metric	Valion Bio, Inc. Common Stock	MEDICAL INFO SYS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.23M	$1.68B	$6.87B	$12.26B
Dividend Yield	N/A	N/A	2.67%	9.79%
P/E Ratio	-0.04	74.42	27.14	23.64
Price / Sales	N/A	62.75	517.08	89.45
Price / Cash	N/A	26.11	50.54	59.64
Price / Book	0.04	4.98	10.28	6.07
Net Income	-$8.88M	-$54.76M	$3.60B	$331.99M
7 Day Performance	-41.19%	-6.95%	-1.27%	-0.63%
1 Month Performance	-48.56%	-2.60%	-0.37%	-2.00%
1 Year Performance	-92.89%	-11.12%	18.30%	13.62%

Valion Bio, Inc. Common Stock Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VBIO Valion Bio, Inc. Common Stock	0.4634 of 5 stars	$0.30 +3.8%	N/A	-93.2%	$1.23M	N/A	N/A	10	Short Interest Increase Gap Down High Trading Volume
VVOS Vivos Therapeutics	2.1553 of 5 stars	$0.41 +0.8%	$2.80 +578.1%	-92.7%	$5.69M	$17.44M	N/A	160
PAVM PAVmed	3.2776 of 5 stars	$6.10 +7.6%	$56.00 +818.0%	-73.0%	$5.65M	$70K	N/A	90
ITOC Itonic	0.8073 of 5 stars	$0.32 -2.3%	N/A	N/A	$5.57M	$520K	N/A	N/A	Positive News
INBS Intelligent Bio Solutions	0.8016 of 5 stars	$2.29 +1.8%	N/A	-90.8%	$5.38M	$3.05M	N/A	10	News Coverage Positive News High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VBIO) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Valion Bio, Inc. Common Stock (VBIO) Competitors

VBIO vs. VVOS, PAVM, ITOC, INBS, and CLGN

How does Valion Bio, Inc. Common Stock compare to Vivos Therapeutics?

Summary

How does Valion Bio, Inc. Common Stock compare to PAVmed?

Summary

How does Valion Bio, Inc. Common Stock compare to Itonic?

Summary

How does Valion Bio, Inc. Common Stock compare to Intelligent Bio Solutions?

Summary

How does Valion Bio, Inc. Common Stock compare to CollPlant Biotechnologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VBIO vs. The Competition

Valion Bio, Inc. Common Stock Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Valion Bio, Inc. Common Stock (VBIO) Competitors

VBIO vs. VVOS, PAVM, ITOC, INBS, and CLGN

How does Valion Bio, Inc. Common Stock compare to Vivos Therapeutics?

Is VVOS or VBIO more profitable?

Which has more volatility and risk, VVOS or VBIO?

Do analysts prefer VVOS or VBIO?

Does the media favor VVOS or VBIO?

Do insiders and institutionals believe in VVOS or VBIO?

Which has preferable earnings & valuation, VVOS or VBIO?

Summary

How does Valion Bio, Inc. Common Stock compare to PAVmed?

Do institutionals and insiders have more ownership in PAVM or VBIO?

Do analysts recommend PAVM or VBIO?

Which has more volatility and risk, PAVM or VBIO?

Is PAVM or VBIO more profitable?

Which has preferable valuation & earnings, PAVM or VBIO?

Does the media prefer PAVM or VBIO?

Summary

How does Valion Bio, Inc. Common Stock compare to Itonic?

Which has more risk and volatility, VBIO or ITOC?

Which has better valuation & earnings, VBIO or ITOC?

Does the media favor VBIO or ITOC?

Do analysts rate VBIO or ITOC?

Do insiders and institutionals have more ownership in VBIO or ITOC?

Is VBIO or ITOC more profitable?

Summary

How does Valion Bio, Inc. Common Stock compare to Intelligent Bio Solutions?

Do analysts rate VBIO or INBS?

Is VBIO or INBS more profitable?

Does the media favor VBIO or INBS?

Which has more volatility and risk, VBIO or INBS?

Which has higher valuation and earnings, VBIO or INBS?

Do institutionals & insiders believe in VBIO or INBS?

Summary

How does Valion Bio, Inc. Common Stock compare to CollPlant Biotechnologies?

Which has more risk & volatility, VBIO or CLGN?

Which has preferable valuation and earnings, VBIO or CLGN?

Do analysts prefer VBIO or CLGN?

Do insiders and institutionals believe in VBIO or CLGN?

Is VBIO or CLGN more profitable?

Does the media favor VBIO or CLGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VBIO vs. The Competition

Valion Bio, Inc. Common Stock Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools